Neptune, Aker BioMarine Bury Patent Hatchet
This article was originally published in The Rose Sheet
The firms say their patent cross-licensing agreement ends all outstanding litigation. Aker gets access to Neptune's composition patents for $10m over a period of 15 months, and Neptune has rights to Aker's select krill oil-related patent portfolio for $4m.
You may also be interested in...
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”
Proposal for simultaneous Rx and OTC sales of same drug at same dose and indication has CHPA hoping FDA acknowledges Pataday and Voltaren Arthritis Relief are competing with Rx equivalents even though elimination of prescription NDAs was part of approvals for the two switches.